Basilar Artery Occlusion, Ischemic Stroke, Large Core Infarct
Conditions
Brief summary
This multicenter retrospective registry study evaluates the safety and effectiveness of endovascular therapy versus medical therapy for acute large-core basilar artery occlusion. It also investigates clinical, imaging, and laboratory factors associated with functional outcomes and mortality. Patients are grouped according to the treatment received in routine clinical practice.
Interventions
PROCEDUREEndovascular Therapy
Endovascular therapy performed as part of routine clinical care for acute basilar artery occlusion, including mechanical thrombectomy with stent retriever and/or aspiration. Rescue angioplasty and/or intracranial stenting may be used at the operator's discretion. Peri-procedural management and concomitant medical therapy follow local standard practice.
Sponsors
Xuanwu Hospital, Beijing
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥18 years, men or women. 2. Occlusion (TIMI 0-1) of the basilar artery or intracranial segments of both vertebral arteries (V4) as evidenced by CTA/MRA/DSA. 3. Time from symptom onset (or last known well) to treatment (endovascular therapy or medical therapy) ≤7 days. 4. Patients with large core infarction in the posterior circulation, defined as a posterior circulation Acute Stroke Prognosis Early CT score (pc-ASPECTS) score of 0-5 on CT angiography source images or MR with diffusion-weighted imaging or non-contrast CT.
Exclusion criteria
1. Subjects with occlusions in both anterior and posterior circulation. 2. CT or MR evidence of hemorrhage (the presence of microbleeds on MRI is allowed). 3. Missing key clinical information (e.g., unavailable baseline NIHSS, unclear symptom onset/last known well time, or missing major treatment information including whether EVT was performed). 4. Baseline NIHSS score \<6. 5. Woman of childbearing potential who is known to be pregnant or lactating or who has a positive pregnancy test on admission. 6. Missing follow-up outcomes at 90 days. 7. Any other condition judged by investigators to substantially affect analysis or interpretation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of Patients Achieving mRS 0-3 at 90 Days | 90 days | The modified Rankin scale (range, 0 \[no symptoms\] to 6 \[death\]). Higher scores mean a worse outcome. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Ordinal Shift analysis of mRS at 90 days | 90 days | The modified Rankin scale (range, 0 \[no symptoms\] to 6 \[death\]) |
| Rate of All-Cause Mortality at 90 Days | 90 days | Death from any cause within 90 days. |
| Rate of Symptomatic Intracranial Hemorrhage | 24 (-2/+12) hours | — |
| Proportion of Patients Achieving mRS 0-3 at 1 year | 1 year | The modified Rankin scale (range, 0 \[no symptoms\] to 6 \[death\]). Higher scores mean a worse outcome. |
Countries
China
Contacts
CONTACTChuanhui Li
Outcome results
None listed